首页> 中文期刊> 《上海医药》 >美国专利重复授权审查标准研究及对我国的启示

美国专利重复授权审查标准研究及对我国的启示

         

摘要

通过分析美国近期发生的“Lilly vs Teva”生物医药专利重复授权纠纷案,深入研究美国专利重复授权的审查标准,在此基础上讨论我国目前重复授权的审查标准,指出存在的问题及可能带来的一些不利影响。最后结合美国重复授权审查标准,对我国重复授权审查标准的完善提出建议。%The examination standard for double patenting in the U.S. was deeply studied by analyzing the bio-pharmaceutical patent disputes concerning double patenting between Eli Lilly and Teva. On this basis, the examination standard of double patenting in China was discussed and the problems and possible adverse impact were also pointed out. And ifnally, several pieces of reasonable suggestions were proposed so as to complete Chinese examination standard of double patenting based on that in the U.S..

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号